Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5147213 | 0.88 | SLC18A3 (0.39) | SLC18A3ABCB1PIK3CDMEN1KMT2A | |
| SCHEMBL5144567 | 0.80 | SLC18A3 (0.43) | SLC18A3ABCB1MEN1KMT2APOLB | |
| SCHEMBL5144884 | 0.79 | ABCB1 (0.44) | SLC18A3ABCB1MEN1KMT2AALDH1A1 | |
| SCHEMBL5146384 | 0.76 | ALDH1A1 (0.47) | SLC18A3MEN1KMT2AALDH1A1 | |
| SCHEMBL5214868 | 0.72 | KMT2A (0.39) | MEN1KMT2AALDH1A1 | |
| SCHEMBL3975559 | 0.70 | SLC18A3 (0.43) | SLC18A3ABCB1PIK3CDPOLB | |
| SCHEMBL5633729 | 0.68 | PIK3CD (0.52) | PIK3CDMEN1KMT2AALDH1A1 | |
| SCHEMBL5144569 | 0.67 | MAPT (0.44) | SLC18A3ABCB1MEN1KMT2APOLB | |
| SCHEMBL1306324 | 0.67 | PIK3CD (0.45) | PIK3CDPOLBALDH1A1 | |
| SCHEMBL5214576 | 0.66 | ABCB1 (0.44) | SLC18A3ABCB1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575591-A4 | HETEROCYCLES AND USES THEREOF | ARIAD PHARMA INC (US) | 2007-09-12 | — | — | EP | disclosed |
| US-7238679-B2 | Heterocycles and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| EP-1575591-A1 | HETEROCYCLES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
| US-20040171586-A1 | Heterocycles and uses thereof | ARIAD PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004058267-A1 | HETEROCYCLES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | SLC18A3 1355/4885ABCB1 661/4885PIK3CD 4767/4885 |
| US-20040171586-A1 | Heterocycles and uses thereof | CBR1, CBR3, RCOR1 | SLC18A3 3355/4885ABCB1 2320/4885PIK3CD 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.